<?xml version="1.0" encoding="UTF-8"?>
<p id="p0100">Ruxolitinib has been found to be effective against inflammatory and autoimmune diseases, and is in late-stage development as a topical ointment for atopic dermatitis. Twenty trials are currently testing the efficacy of the drug in COVID-19 patients.</p>
